Results 31 to 40 of about 51,359 (234)
Pharmacologic approaches against advanced glycation end products (ages) in diabetic cardiovascular disease [PDF]
, 2015 Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients.
Avtaar Singh, Sanjeet Singh +6 more
core +2 more sources
PPAR Research, 2018 Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD.
Hwa Young Ahn +5 more
doaj +1 more source
Anti-oxidants in Parkinson's disease therapy: a critical point of view [PDF]
, 2016 Parkinson's disease (PD) is a degenerative neurological syndrome, which is characterized by the preferential death of dopaminergic (DAergic) neurons in the SubstantiaNigra.
Beltramini, Mariano +3 more
core +2 more sources
Journal of Lipid Research, 2010 Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and ...
Lin-Hua Zhang +4 more
doaj +1 more source
Scientific Reports, 2023 Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM).
Hsin-Chung Lin +8 more
doaj +1 more source
Effects of Pioglitazone on Stearoyl-CoA Desaturase in Obese Zucker fa/fa Rats
Journal of Pharmacological Sciences, 2007 The effects of a peroxisome proliferator activated receptor γ (PPARγ) agonist on hepatic stearoyl-CoA desaturase (SCD) in insulin-resistant and obese Zucker fa/fa rats were studied.
Tomoaki Toyama +5 more
doaj +1 more source
The Effect of Co-administration of Pioglitazone and Simvastatin on Insulin Resistance Parameters and PPAR.γ Expression in Insulin-resistant Rats [PDF]
Journal of Kerman University of Medical Sciences, 2017 Backgrounds: Insulin resistance is a pathological condition associated with metabolic syndrome. In this condition, insulin action in liver, muscles, and adipocytes decreases which leads to hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Gholam Abbas Mohammadi +3 more
doaj
The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: A bench to bedside review [PDF]
, 2014 INTRODUCTION: The treatment of type 2 diabetes mellitus (T2DM) continues to pose challenges for clinicians and patients. The dramatic rise in T2DM prevalence, which has paralleled the rise in obesity, has strained the healthcare system and prompted the ...
McGill, Janet B
core +2 more sources
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]
Diabetes & Metabolism Journal, 2016 BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim +16 more
doaj +1 more source
Cardiovascular Diabetology, 2017 Background and aims Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary ...
Marit de Jong +4 more
doaj +1 more source